Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Response of AryoSeven in Hemophilia With Inhibitors
NCT04789954Phase 1Completed
- Sponsor
- AryoGen Biopharma
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AryoSeven in hemophilia A and hemophilia B (HB) (5 arms), sponsored by AryoGen Biopharma. Primary endpoint: Lag time of the thrombin generation curve. Started Dec 2020; status: completed.
02
Drugs
AryoSeven
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT04789954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789954.